Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1987 2
1989 2
1992 1
1998 1
1999 2
2000 1
2001 2
2004 5
2005 5
2006 4
2007 3
2008 7
2009 5
2010 11
2011 14
2012 11
2013 7
2014 13
2015 10
2016 11
2017 10
2018 8
2019 4
2020 5
2021 1
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 21393407

136 results
Results by year
Filters applied: . Clear all
Page 1
Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.
Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Hygino da Cruz LC Jr, et al. AJNR Am J Neuroradiol. 2011 Dec;32(11):1978-85. doi: 10.3174/ajnr.A2397. Epub 2011 Mar 10. AJNR Am J Neuroradiol. 2011. PMID: 21393407 Free article. Review.
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Wen PY, et al. J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15. J Clin Oncol. 2010. PMID: 20231676
Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy.
Yang I, Huh NG, Smith ZA, Han SJ, Parsa AT. Yang I, et al. Neurosurg Clin N Am. 2010 Jan;21(1):181-6. doi: 10.1016/ Neurosurg Clin N Am. 2010. PMID: 19944976 Review.
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.
Tsien C, Galbán CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, Junck L, Meyer CR, Rehemtulla A, Lawrence T, Ross BD. Tsien C, et al. J Clin Oncol. 2010 May 1;28(13):2293-9. doi: 10.1200/JCO.2009.25.3971. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368564 Free PMC article.
Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum--use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI.
Fatterpekar GM, Galheigo D, Narayana A, Johnson G, Knopp E. Fatterpekar GM, et al. AJR Am J Roentgenol. 2012 Jan;198(1):19-26. doi: 10.2214/AJR.11.7417. AJR Am J Roentgenol. 2012. PMID: 22194475 Review.
Clinical trial end points for high-grade glioma: the evolving landscape.
Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Reardon DA, et al. Neuro Oncol. 2011 Mar;13(3):353-61. doi: 10.1093/neuonc/noq203. Epub 2011 Feb 9. Neuro Oncol. 2011. PMID: 21310734 Free PMC article. Review.
Neuroimaging and genetic influence in treating brain neoplasms.
Hygino da Cruz LC Jr, Kimura M. Hygino da Cruz LC Jr, et al. Neuroimaging Clin N Am. 2015 Feb;25(1):121-40. doi: 10.1016/j.nic.2014.09.011. Neuroimaging Clin N Am. 2015. PMID: 25476517 Review.
Perfusion magnetic resonance imaging for parametric response maps in tumors: is it really that easy?
Heiland S, Wick W, Bendszus M. Heiland S, et al. J Clin Oncol. 2010 Oct 10;28(29):e591; author reply e592. doi: 10.1200/JCO.2010.30.3586. Epub 2010 Sep 13. J Clin Oncol. 2010. PMID: 20837945 No abstract available.
Pseudoprogression and pseudoresponse in the treatment of gliomas.
Brandsma D, van den Bent MJ. Brandsma D, et al. Curr Opin Neurol. 2009 Dec;22(6):633-8. doi: 10.1097/WCO.0b013e328332363e. Curr Opin Neurol. 2009. PMID: 19770760 Review.
Pros and cons of current brain tumor imaging.
Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF. Ellingson BM, et al. Neuro Oncol. 2014 Oct;16 Suppl 7(Suppl 7):vii2-11. doi: 10.1093/neuonc/nou224. Neuro Oncol. 2014. PMID: 25313235 Free PMC article. Review.
136 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page